Company: WHWK
Filing Date: 2025-02-05
Form Type: DEFA14A
Source: 0001193125-25-020865
Chunk: 4

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-02-05
Form: DEFA14A
Chunk 4
---
 transactions in December 2024, our stock price rose 46% in the first day of trading and has remained significantly above the pre-announcementtrading price. Recently, our stock has been trading at approximately twice the level at which it closed the day after we announced the PRECISION1 trial discontinuation. To support our transformation, we are asking for your support at our upcoming Special Meeting, which will be held on February 28, 2025. We encourage you to vote for all proposals on the agenda. Key among those proposals are:

| • |     | The Divestiture Proposal, which will enable us to realize the full and fair value of FYARRO; |

| • |     | The PIPE Financing Proposal, which will help ensure we have the resources we need to develop our 
 revitalized ADC pipeline; and                                                                    |

| • |     | The Equity Plan Proposal, which will enable the Company to align the incentives of our key executives, 
 employees and other eligible plan participants with those of our stockholders.                         |

These proposals, and the transactions they facilitate, are critical to Aadi’s future. With your support, we can write the next chapter in Aadi’s history and maximize long-term stockholder value. Sincerely, /s/ David Lennon, Ph.D. David J. Lennon Ph.D. President & Chief Executive Officer, On behalf of the Aadi Bioscience Board of Directors Forward-Looking Statements This communication contains certain forward-looking statements regarding the business of Aadi Bioscience that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company’s current beliefs and expectations and may include, but are not limited to, statements relating to: the timing and completion of the proposed sale of FYARRO to Kaken Pharmaceuticals and the anticipated timing of the closing of the transaction; expectations regarding the timing, closing and completion of the PIPE financing; Aadi’s expected cash position at the closing and cash runway of the Company following the sale of FYARRO and PIPE financing; the future operations of Aadi; the development and potential benefits of any of Aadi’s product candidates, including the preclinical ADC assets proposed to be licensed from WuXi; anticipated preclinical and clinical development activities and related timelines, including the expected timing for announcement of data and other preclinical and clinical results and potential submission of IND filings for one or more product candidates; and other statements that are not historical fact. Actual results could differ